Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Impact BioMedical to merge with Zoar Ltd.

PUBLIC · IBOSep 11, 2026about 10 hours ago

Acquiring Company

Impact BioMedical

Acquired Company

Zoar Ltd

TexasBiotechnologyHealth CareBiotechnologyHealth Care

Description

Impact BioMedical Inc. and Zoar Ltd. are planning a merger that will create a new company with extensive expertise in pharmaceuticals. Following the completion of the merger, Impact stockholders will receive shares of Zoar Ltd. The merger aims to enhance capabilities in manufacturing and clinical development for critical drugs.

Company Information

Company

Impact BioMedical

Location

Texas, United States

About

Impact BioMedical Inc. is a biopharmaceutical developer that creates innovative treatments and solutions. The company is publicly traded on the New York Stock Exchange American. It focuses on advancing biotechnology to meet unmet medical needs. Impact BioMedical aims to improve patient outcomes through its intellectual property and innovative products.

Don't miss Impact BioMedical's next move

Get an email the moment Impact BioMedical makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Impact BioMedical's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Zoar Ltd?

Zoar Ltd was acquired by Impact BioMedical, based in Texas. The deal was reported on September 11, 2026. Impact BioMedical Inc. is a biopharmaceutical developer that creates innovative treatments and solutions. The company is publicly traded on the New York Stock Exchange American. Impact BioMedical is publicly traded (IBO) and operates in Biotechnology.

When did Impact BioMedical acquire Zoar Ltd?

Impact BioMedical's acquisition of Zoar Ltd was reported on September 11, 2026. Impact BioMedical Inc. and Zoar Ltd. are planning a merger that will create a new company with extensive expertise in pharmaceuticals. Following the completion of the merger, Impact stockholders will receive shares of Zoar Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Zoar Ltd do?

Zoar Ltd. specializes in the production of pharmaceutical ingredients and intermediates. The company is poised to contribute expertise in human health and wellness markets. It has significant intellectual property in its field. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.